Laboratory Assessment of HDL Heterogeneity and Function
Open Access
- 1 May 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (5) , 788-800
- https://doi.org/10.1373/clinchem.2007.101923
Abstract
Background: Plasma concentrations of HDL cholesterol (HDL-C) and its major protein component apolipoprotein (apo) A-I are strongly inversely associated with cardiovascular risk, leading to the concept that therapy to increase HDL-C and apoA-I concentrations would be antiatherosclerotic and protective against cardiovascular events. The recent failure of the drug torcetrapib, a cholesteryl ester transfer protein inhibitor that substantially increased HDL-C concentrations, has brought focus on the issues of HDL heterogeneity and function as distinct from HDL-C concentrations.Content: This review addresses the current state of knowledge regarding assays of HDL heterogeneity and function and their relationship to cardiovascular disease. HDL is highly heterogeneous, with subfractions that can be identified on the basis of density, size, charge, and protein composition, and the concept that certain subfractions of HDL may be better predictors of cardiovascular risk is attractive. In addition, HDL has been shown to have a variety of functions that may contribute to its cardiovascular protective effects, including promotion of macrophage cholesterol efflux and reverse cholesterol transport and antiinflammatory and nitric oxide–promoting effects.Summary: Robust laboratory assays of HDL subfractions and functions and validation of the usefulness of these assays for predicting cardiovascular risk and assessing response to therapeutic interventions are critically important and of great interest to cardiovascular clinicians and investigators and clinical chemists.Keywords
This publication has 122 references indexed in Scilit:
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJournal of Clinical Investigation, 2007
- Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary AtherosclerosisJAMA, 2007
- Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatinJournal of Internal Medicine, 2006
- HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayJournal of Clinical Investigation, 2006
- Relation Between On-Treatment Increments in Serum High-Density Lipoprotein Cholesterol Levels and Cardiac Mortality in Patients With Coronary Heart Disease (from the Bezafibrate Infarction Prevention Trial)The American Journal of Cardiology, 2006
- Associations of HDL 2 and HDL 3 Subfractions With Ischemic Heart Disease in MenArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Higher level of plasma cholesteryl ester transfer activity from high-density lipoprotein to Apo B-containing lipoproteins in subjects with angiographically detectable coronary artery diseaseClinical Cardiology, 1996
- Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivityThe American Journal of Cardiology, 1991
- High-Density Lipoprotein — The Clinical Implications of Recent StudiesNew England Journal of Medicine, 1989